PubMed Health⌕ Search

Biomedical subjects

T Bannister

Publications and source records attributed to T Bannister.

10 recordsLinked to original sources

Susceptibility of clinical isolates of Enterobacteriaceae to BL-S640, a new oral cephalosporin.

The in vitro activity of BL-S640, a 7-(2-aryl-2-aminoacetamido)-3-(heterocyclic-thiomethyl) cephalosporin, was evaluated against 338 clinical isolates of Enterobacteriaceae in comparison with ampicillin, cephalothin, cefazolin, and cephalexin. Against Escherichia coli, BL-S640 was as active as cefazolin and more active than ampicillin, cephalothin, and cephalexin. BL-S640 was as effective as the other cephalosporins tested and far more active than ampicillin against Klebsiella and was more active than cephalexin against Proteus mirabilis and the indole-positive Proteus. The majority of Enterobacter, Serratia, and Citrobacter were resistant to ampicillin and all the cephalosporins tested. With rare exceptions, the zone of inhibition by the BL-S640 30-mug disk was either larger or the same as the zone obtained by the cephalothin 30-mug disk in the Kirby-Bauer disk susceptibility test.

Cephalosporins↗

Comparison of the in vitro activity of BL-P1654 with gentamicin and carbenicillin against Pseudomonas aeruginosa.

The in vitro activity of 6-[d-alpha-(3 guanylureido)-phenylacetamido]-penicillanic acid (BL-P1654) was evaluated against 117 clinical isolates of Pseudomonas aeruginosa, many of which were known to be resistant to both gentamicin and carbenicillin. BL-P1654 was two to eight times more active than carbenicillin against P. aeruginosa. However, all 28 highly carbenicillin-resistant isolates (minimal inhibitory concentration [MIC] > 500 mug/ml) were also highly resistant to BL-P1654. When an MIC of 32 mug/ml or less and a zone of inhibition of 12 mm or more by a 10-mug disk were used as criteria indicating susceptibility to BL-P1654, the false-resistance rate by the disk test was 10.6% and the false-susceptibility rate was 4.2%. The combination of BL-P1654 and gentamicin was synergistic against 45 of 70 isolates of P. aeruginosa tested, but synergism was demonstrated against only 4 of 24 highly gentamicin-resistant (MIC > 63 mug/ml), 1 of 12 highly BL-P1654-resistant (MIC > 250 mug/ml) isolates, and none of nine isolates highly resistant to both of these antibiotics.

Carbenicillin↗

In vitro susceptibility of Pseudomonas aeruginosa to carbenicillin and the combination of carbenicillin and gentamicin.

One hundred and eleven strains of Pseudomonas aeruginosa isolated from clinical material were studied for susceptibility to carbenicillin. Of the strains, 80% were inhibited by 125 mug/ml or more. The combination of carbenicillin and gentamicin was shown to have inhibitory and bactericidal synergistic effect on 15 of 16 strains of P. aeruginosa tested. There was poor correlation between the single-disc sensitivity method and the tube dilution method.

Drug Synergism↗